Rapid responses are electronic comments to the editor. They enable our users
to debate issues raised in articles published on bmj.com. A rapid response
is first posted online. If you need the URL (web address) of an individual
response, simply click on the response headline and copy the URL from the
browser window. A proportion of responses will, after editing, be published
online and in the print journal as letters, which are indexed in PubMed.
Rapid responses are not indexed in PubMed and they are not journal articles.
The BMJ reserves the right to remove responses which are being
wilfully misrepresented as published articles or when it is brought to our
attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not
including references and author details. We will no longer post responses
that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
With reference to the recently published article by Pieters
criticising the marketing of interferons1 I wish to point out that the
actions attributed to "Schering" in paragraph 4 on page 1232 do not refer
to Schering Healthcare Limited nor to our parent company, Schering AG.
As a well-respected company in the field of interferon beta research and
development, we feel it is important that this is clarified at the
Jacqueline C Napier MRCP
Associate Medical Director
1. Pieters, T. Marketing medicines through randomised controlled trials:
the case of interferon. BMJ 1998; 317: 1231-1233.